2025
A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus
Peng X, Klingensmith G, Hsia D, Xie Y, Czerniak R, Tamborlane W, Shah A. A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus. Diabetes Therapy 2025, 1-19. PMID: 40032809, DOI: 10.1007/s13300-025-01700-3.Peer-Reviewed Original ResearchType 2 diabetes mellitusAlogliptin treatmentEfficacy endpointPediatric patientsAntihyperglycemic therapyOral dipeptidyl peptidase-4 inhibitorHbA1c levelsRandomized phase 3 studyDipeptidyl peptidase-4 inhibitorsSafety of alogliptinPlacebo-controlled trialPhase 3 studyBaseline to weekPeptidase-4 inhibitorsBody mass indexImprove glycemic controlDouble-blindPlacebo groupSecondary endpointsBackground metforminSchedule APharmacological therapyMass indexGlycosylated hemoglobinInsulin therapySociodemographic and Systems Risk Factors Associated With Nil by Mouth Noncompliance and Day-of-Procedure Cancellations: A Retrospective Multicenter Case-Control Study.
Goldstein D, Jimenez N, Faulk D, Jones J, Reece-Nguyen T, Gooden C, Markowitz D, Dalal P. Sociodemographic and Systems Risk Factors Associated With Nil by Mouth Noncompliance and Day-of-Procedure Cancellations: A Retrospective Multicenter Case-Control Study. Anesthesia & Analgesia 2025 PMID: 40036165, DOI: 10.1213/ane.0000000000007451.Peer-Reviewed Original ResearchCase-control studySystemic risk factorsRisk factorsNPO guidelinesRetrospective multicenter case-control studyMulticenter retrospective case-control studyRetrospective case-control studyMulticenter case-control studySingle-center studyDay of procedureMultivariate logistic regressionPublic health insuranceYears of ageLanguage of carePediatric patientsMulticenter studyAffected patientsNoncompliance eventsHealth insurance typeIncreased riskMultivariate analysisPrimary outcomeSecondary outcomesElective proceduresHealth insuranceEliglustat substrate reduction therapy in children with Gaucher disease type 1
Ain N, Saith A, Ruan A, Yang R, Burton A, Mistry P. Eliglustat substrate reduction therapy in children with Gaucher disease type 1. Frontiers In Pediatrics 2025, 13: 1543136. PMID: 40083427, PMCID: PMC11903696, DOI: 10.3389/fped.2025.1543136.Peer-Reviewed Original ResearchEnzyme replacement therapySubstrate reduction therapyGD1 patientsPediatric patientsReduction therapyOral substrate reduction therapyPrimary outcomeAlternative to enzyme replacement therapyIntravenous enzyme replacement therapyLevels compared to baselineGaucher disease type 1Indicator of disease activityParent-reported qualityCYP2D6 metabolizer statusRare lysosomal storage disorderProspective case seriesGaucher diseaseType 1 Gaucher diseaseQuality of lifeDisease indicationsLysosomal storage disorderPROMIS questionnairesReplacement therapyCase seriesClinical benefitIncidence and Risk Factors for Posttraumatic Osteoarthritis After Primary ACL Reconstruction in Pediatric Patients: A National Database Study
Moran J, Gouzoulis M, Kunze K, LaPrade C, Grauer J, Hewett T, Chahla J, Jimenez A, McKay S, Fabricant P, LaPrade R, Franklin C. Incidence and Risk Factors for Posttraumatic Osteoarthritis After Primary ACL Reconstruction in Pediatric Patients: A National Database Study. Orthopaedic Journal Of Sports Medicine 2025, 13: 23259671251313754. PMID: 39926589, PMCID: PMC11806457, DOI: 10.1177/23259671251313754.Peer-Reviewed Original ResearchPrimary ACLRAnterior cruciate ligament (ACL) reconstructionRisk factorsPosttraumatic osteoarthritisPediatric patientsMale sexRestorative proceduresTibial eminence avulsion fractureLysis of adhesionsYears of follow-up dataPrimary ACL reconstructionACL injury diagnosisMultiligament knee injuriesNational database studyCase-control studyConcomitant partial meniscectomyFollow-up dataMultivariate logistic regressionLevel of evidenceJuvenile idiopathic arthritisDevelopment of posttraumatic osteoarthritisInjury diagnosisKnee injuriesKnee osteoarthritisCartilage proceduresColonic Manometry in Pediatric Patients with Spina Bifida: Results from a Retrospective Cohort Study
Shan A, Duel B, Phillips T, Buchanan P, Rodriguez L, Patel D. Colonic Manometry in Pediatric Patients with Spina Bifida: Results from a Retrospective Cohort Study. Children 2025, 12: 184. PMID: 40003286, PMCID: PMC11854801, DOI: 10.3390/children12020184.Peer-Reviewed Original ResearchSlow transit constipationRetrospective cohort studyColonic transit timeColonic manometryBowel dysfunctionColonic motilityAnorectal manometryAnorectal dysfunctionSB patientsStimulant laxativesCohort studySpina bifidaNeurogenic bowel dysfunctionDefecation-related symptomsEvaluate colonic motilityConservative therapyPediatric patientsSurgical interventionInvasive testingBowel regimensBowel symptomsFurther treatmentCM findingsTreatment outcomesDiagnostic findingsPOCUS the Pelvis: A Case Series of Timely Diagnoses in Pediatric Patients With Abdominal Pain.
Leviter J, Shah R, Constantine E, Riera A. POCUS the Pelvis: A Case Series of Timely Diagnoses in Pediatric Patients With Abdominal Pain. Pediatric Emergency Care 2025 PMID: 39895170, DOI: 10.1097/pec.0000000000003348.Peer-Reviewed Original ResearchRobotic Congenital Cardiac Surgery Practice Worldwide: A Systematic Review
Lee M, Amabile A, Hameed I, Antonios J, Awad A, Brackett A, Krane M, Gruber P, Geirsson A. Robotic Congenital Cardiac Surgery Practice Worldwide: A Systematic Review. Journal Of Cardiac Surgery 2025, 2025 DOI: 10.1155/jocs/4692522.Peer-Reviewed Original ResearchCase reportTreatment of congenital heart diseaseAdult cardiac surgery patientsHighest incidence of morbidityCannulation-related complicationsImproved surgeon experienceCongenital heart diseaseCardiac surgery patientsSmall case seriesIncidence of morbidityIndependent reviewers screened titles/abstractsInconsistent outcome reportingNewcastle-Ottawa ScaleNonrandomized observational studyCardiac surgery operationsComprehensive literature searchCongenital operationsCongenital diagnosisCongenital surgeryPediatric patientsPleural effusionCase seriesRetrospective studySurgeon experienceHeart blockPrevalence and Risk Factors for Medial Meniscus Ramp Lesions in the Setting of Pediatric Anterior Cruciate Ligament Injuries: A Systematic Review and Meta-analysis
Moran J, Lee M, Fong S, LaPrade C, Kunze K, Fabricant P, Chahla J, Jimenez A, LaPrade R. Prevalence and Risk Factors for Medial Meniscus Ramp Lesions in the Setting of Pediatric Anterior Cruciate Ligament Injuries: A Systematic Review and Meta-analysis. Journal Of Pediatric Orthopaedics 2025, 45: 183-193. PMID: 39840766, DOI: 10.1097/bpo.0000000000002900.Peer-Reviewed Original ResearchMedial meniscus ramp lesionsConcomitant lateral meniscus tearMagnetic resonance imagingPediatric patientsBone marrow edemaLateral meniscus tearsACL reconstructionRisk factorsCollateral ligament injuriesLigament injuriesSystematic reviewRamp lesionsMarrow edemaMale sexMeta-analysisOdds ratioAnterior cruciate ligament (ACL) injuryMeniscus tearsPreoperative magnetic resonance imagingAssociated with anterior cruciate ligament (ACL) injuryAnterior cruciate ligament injuryRisk of graft failureSkeletal maturityCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsAge‐associated differences in FIRES: Characterizing prodromal presentation and long‐term outcomes via the web‐based NORSE/FIRES Family Registry
Kazazian K, Gaspard N, Hirsch L, Kellogg M, Hocker S, Wong N, Farias‐Moeller R, Eschbach K, Gofton T. Age‐associated differences in FIRES: Characterizing prodromal presentation and long‐term outcomes via the web‐based NORSE/FIRES Family Registry. Epilepsia 2025, 66: e35-e40. PMID: 39804054, PMCID: PMC11908657, DOI: 10.1111/epi.18260.Peer-Reviewed Original ResearchConceptsFamily RegistryFebrile infection-related epilepsy syndromeAnti-seizure medicationsSelf-reported qualityQuality of lifePediatric patientsLong-term outcomesWeb-based registryProdromal symptomsAnxiety outcomesPoor cognitionAnti-seizure medication useClinical presentationSeizure burdenAdult survivorsProdromal presentationInternational web-based registryBad moodRegistryAge groupsRefractory status epilepticusAdultsCognitive outcomesOutcomesAge-associated differencesLow-Dose Oral Minoxidil Initiation for Patients With Hair Loss
Akiska Y, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender V, Castelo-Soccio L, Cotsarelis G, Craiglow B, Desai N, Doche I, Duque-Estrada B, Elston D, Goh C, Goldberg L, Grimalt R, Jabbari A, Jolliffe V, King B, LaSenna C, Lenzy Y, Lester J, Lortkipanidze N, Sicco K, McMichael A, Meah N, Mesinkovska N, Miteva M, Mostaghimi A, Ovcharenko Y, Piliang M, Piraccini B, Rakowska A, Salkey K, Schmidt A, Shapiro J, Sibbald C, Sinclair R, Suchonwanit P, Taylor S, Tosti A, Vañó-Galván S, Wall D, Fu J. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss. JAMA Dermatology 2025, 161: 87-95. PMID: 39565602, DOI: 10.1001/jamadermatol.2024.4593.Peer-Reviewed Original ResearchLow-dose oral minoxidilOral minoxidilExpert consensus statementTopical minoxidilHair lossPediatric patientsConsensus statementModified Delphi processDelphi consensus processEfficacy of topical minoxidilResults of small studiesInternational expert consensus statementsTreating pediatric patientsAdverse effect profileLong-term safetyOff-label useSpecialty consultationOff-label prescribingDelphi processSurvey roundsEvidence-based dataConsensus processExpert panelSublingual minoxidilThird round
2024
Evaluation and management of pediatric refractory constipation: Recommendations from the NASPGHAN neurogastroenterology and motility committee
Kilgore A, Boruta M, Ambartsumyan L, Suarez R, Patel D, Wood R, Darbari A, Rodriguez L. Evaluation and management of pediatric refractory constipation: Recommendations from the NASPGHAN neurogastroenterology and motility committee. Journal Of Pediatric Gastroenterology And Nutrition 2024, 80: 353-373. PMID: 39741384, DOI: 10.1002/jpn3.12390.Peer-Reviewed Original ResearchType 1 Diabetes in Children and Adolescents
Hu P, Van Name M, Stephenson K, Sikes K, Tamborlane W. Type 1 Diabetes in Children and Adolescents. 2024, 809-835. DOI: 10.1007/978-3-031-66296-6_30.Peer-Reviewed Original ResearchType 1 diabetesRelative insufficiency of insulinContinuous glucose monitoringMacrovascular complications of diabetesDevelopment of diabetes-related complicationsComplications of diabetesInsufficiency of insulinAdvanced diabetes technologiesPediatric patientsMetabolic derangementsTherapeutic advancesDiabetes mellitusDiabetes-related complicationsMacrovascular complicationsControl of T1DReal-time continuous glucose monitoringMetabolic controlDiabetesLifelong disorderRelative insufficiencyChildren and Restraints Study in Emergency Ambulance Transport-Cardiopulmonary Resuscitation (CARSEAT-CPR): An Observational Cohort Study of a Simulated Pediatric Cardiac Arrest.
Cochran-Caggiano N, Tse W, Swinburne C, Lang N, Till S, Donovan S, Woodson M, Dailey M. Children and Restraints Study in Emergency Ambulance Transport-Cardiopulmonary Resuscitation (CARSEAT-CPR): An Observational Cohort Study of a Simulated Pediatric Cardiac Arrest. Pediatric Emergency Care 2024 PMID: 39642211, DOI: 10.1097/pec.0000000000003316.Peer-Reviewed Original ResearchBasic life supportCompression fractionMoving ambulanceSimulated pediatric cardiac arrestBasic life support skillsNo significant differenceChest compression fractionCardiac arrestAmerican Heart Association recommendationsDepth of compressionInfant cardiac arrestSignificant differencePediatric cardiac arrestObservational cohort studyCompression depthProviders' abilityPediatric manikinInfant manikinCohort studyAssociation recommendationsPatient resuscitationPediatric patientsLife supportClinical significanceInfant testingEmergency Department Visits Following Supracondylar Humerus Fractures
Gouzoulis M, Yang A, Joo P, Kaszuba S, Frumberg D, Grauer J. Emergency Department Visits Following Supracondylar Humerus Fractures. Journal Of Pediatric Orthopaedics 2024, 45: 128-133. PMID: 39808740, DOI: 10.1097/bpo.0000000000002866.Peer-Reviewed Original ResearchPediatric supracondylar humerus fracturesSupracondylar humerus fracturesHumerus fracturesEmergency departmentSurgical interventionManagement of pediatric supracondylar humerus fracturesHistory of ED visitsOdds ratioED visitsMultivariate logistic regressionPediatric patientsInitial managementPediatric fracturesPredictive factorsEmergency department visitsMultivariate analysisQuality improvement measuresRisk factorsPatientsTime of visitClinical interestMedicaid insuranceAdministrative databasesLogistic regressionDepartment visitsWorldwide Clinical and Real-World Exposure to Baricitinib
Vleugels R, Craiglow B, Mostaghimi A, Olsen E, Sontag A, Denning K, Somani N, Hordinsky M. Worldwide Clinical and Real-World Exposure to Baricitinib. SKIN The Journal Of Cutaneous Medicine 2024, 8: s501. DOI: 10.25251/skin.8.supp.501.Peer-Reviewed Original ResearchLength of therapyClinical trialsAtopic dermatitisTreated with baricitinibAverage length of therapyAge 2 yearsJuvenile idiopathic arthritisYears of ageMonths of ageBaricitinib doseAverage daily doseYrs of agePediatric patientsAcute infectious diseaseDaily doseCOVID-19 infectionAlopecia areataJAK inhibitorsHospitalized patientsIdiopathic arthritisBaricitinibPatientsBlind trialRheumatoid arthritisDisease statesSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial
Merola J, Strober B, Gottlieb A, Mostaghimi A, Hawkes J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s488. DOI: 10.25251/skin.8.supp.488.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementSystemic medicationsConventional systemic treatmentsAverage body surface areaTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageSystemic therapyDosing regimenSystemic treatmentPediatric patientsPustular psoriasisExtent of involvementSpesolimabWeek 4Skin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial
Mostaghimi A, Strober B, Merola J, Gottlieb A, Elewski B, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s489. DOI: 10.25251/skin.8.supp.489.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementWeek 4Disease historyAverage body surface areaTreating generalized pustular psoriasisYear prior to enrollmentLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabDisease courseSkin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsSpesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatmentSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial
Strober B, Merola J, Gottlieb A, Mostaghimi A, Hsiao J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s491. DOI: 10.25251/skin.8.supp.491.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementTreating generalized pustular psoriasisLife-threatening skin diseaseArea of involvementSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabSkin symptomsContinuous treatmentPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsTreatmentInvolvementBody regionsPharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh R, Hartmann P, Olson O, Gupta O, Kumar S, Ibrahim S, Fawaz R, Aqul A, Hassan S. Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease. Journal Of Pediatric Gastroenterology And Nutrition 2024, 80: 14-24. PMID: 39526564, DOI: 10.1002/jpn3.12402.Peer-Reviewed Original ResearchGLP-1RABody mass indexLiver diseasePediatric patientsPediatric obesityEfficacy of GLP-1RADisease progressionGlucagon-like peptide-1 receptor agonistsSteatotic liver diseaseManagement of pediatric patientsPeptide-1 receptor agonistsClinical management of pediatric patientsAdverse liver outcomesInduce weight lossLong-term efficacyHepatic manifestation of obesityLiver enzyme levelsAlternative therapeutic strategiesHalting disease progressionManifestation of obesityNonalcoholic fatty liver diseaseChildhood obesity ratesFatty liver diseaseReceptor agonistsLiver transplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply